Canonic has commenced its cultivation and breeding program of cannabis varieties with unique genomic profiles for the development of medical cannabis products. "The initiation of cannabis cultivation follows: (1) successfully importing widely genetically diverse cannabis lines originating from different territories, (2) establishment of cannabis dedicated R&D facilities, including greenhouses, a molecular lab and tissue culture rooms and (3) receipt of the required regulatory approvals from the Israeli Medical Cannabis Agency (IMCA)," the team with the company explains.
"Canonic achieved an important milestone with the import of a genetically diverse seed collection of cannabis lines originating from different territories. These seeds were specifically selected to be the foundation of Canonic's advanced breeding program and product pipeline consisting of MetaYield - medical cannabis products with a stable increase of total plant active compounds, and Precise product line - medical cannabis with a stable increase of specific plant active compounds."
"Canonic's R&D facilities, of which Canonic today announces the completion of their establishment, are among the largest in Israel and include molecular labs, tissue culture rooms and 22 thousand sq. ft. of controlled greenhouses, integrating the latest technologies for climate control, daylight control, fertilization and irrigation," they further explain. "The company also established a quarantine greenhouse, which has allowed the initiation of cannabis cultivation immediately upon receiving imported cannabis seeds and provides improved flexibility and quality control."
"The company has received the required regulatory approvals for both greenhouses and labs including Good Security Practice (GSP) approval and possession license for cannabis from the Israeli Medical Cannabis Agency (IMCA)."
Canonic's scientific approach for the development of cannabis products with unique genomic profiles is based on decoding the cannabis plant's genome to overcome the current market challenges associated with these products. "To achieve this goal, Canonic employs the use of Evogene's unique technology developed over the past decade, the CPB platform, leveraging deep understanding of plant genomics, Big Data and artificial intelligence," they say. "The Company intends to use the genomic data of the new varieties imported to expand its genomic database and to be integrated in the CPB's computational platforms in order to accelerate development efforts."
Dr. Arnon Heyman, Canonic's CEO stated: "We are excited to kick-off our cultivation and breeding program of cannabis varieties with unique genomic profiles for the development of state-of-the-art medical cannabis products. This achievement is in line with our 2019 milestones, outlined earlier this year, and will allow Canonic to accelerate its product development in the coming year with a focus on achieving unique cannabis varieties addressing specific medical needs. We look forward to update you as we continue to deliver our milestones on the journey to becoming a valuable player in the medical cannabis world."
For more information: